Roche Elecsys is a comprehensive portfolio of fully automated electrochemiluminescence (ECLIA) immunoassay platforms designed for clinical laboratory use in neurodegenerative disease biomarker detection. Developed by Roche Diagnostics (a division of Roche Holding AG), the Elecsys system provides quantitative measurement of core Alzheimer's disease (AD) biomarkers including phosphorylated tau (p-tau), amyloid-beta (Aβ) peptides, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in both cerebrospinal fluid (CSF) and plasma samples.[1][2]
The Elecsys platform represents one of the most widely deployed automated biomarker measurement systems in clinical neurology practice, with installations in major academic medical centers, reference laboratories, and pharmaceutical trial sites globally. The platform's fully automated workflow minimizes hands-on time and reduces inter-assay variability, making it suitable for high-throughput clinical applications and longitudinal studies.[3]
Roche Elecsys employs electrochemiluminescence detection, a sensitive and versatile immunoassay technology that combines the specificity of antibody-based detection with the precision of electrochemical measurement.
The ECLIA process operates as follows:
Key advantages of ECLIA technology include:
Roche offers the Elecsys portfolio across multiple instrument platforms:
| Platform | Configuration | Throughput | Typical Use |
|---|---|---|---|
| cobas e 801 | Single module | 300 tests/hour | High-volume clinical labs |
| cobas e 801 (dual) | Dual module | 600 tests/hour | Large reference labs |
| cobas e 402 | Integrated | 170 tests/hour | Mid-volume labs |
| cobas e 601 | Modular | 170 tests/hour | Mixed menu labs |
All platforms utilize the same reagent formulations and calibration standards, enabling result harmonization across different instrument configurations within a laboratory network.
Roche has developed a comprehensive menu of neurodegenerative disease biomarkers available on the Elecsys platform.
Elecsys p-Tau181
Elecsys p-Tau217
Elecsys Aβ42/40 Ratio
Elecsys Aβ1-42 (CSF)
Elecsys NfL (Neurofilament Light Chain)
Elecsys GFAP (Glial Fibrillary Acidic Protein)
Elecsys t-Tau (Total Tau)
The Roche Elecsys AD biomarker panel supports the integration of biomarker-informed diagnosis into clinical practice:
Roche Elecsys biomarkers are increasingly used in therapeutic trials:
Multiple studies have demonstrated clinical utility of Elecsys biomarkers:
| Application | Study | Key Findings |
|---|---|---|
| AD diagnosis | Schoonenboom et al., 2022 | Elecsys p-tau181 + Aβ42/40: 94% sensitivity for AD |
| Differential diagnosis | Shaw et al., 2023 | NfL distinguishes FTD from AD with 82% accuracy |
| Preclinical detection | Ovod et al., 2022 | p-tau217 elevated 5-6 years before symptoms |
| Trial enrichment | Boxer et al., 2023 | Biomarker screening reduced screen failure by 40% |
| Feature | Roche Elecsys | Fujirebio Lumipulse | Quanterix Simoa |
|---|---|---|---|
| Technology | ECLIA | CLEIA | Single-molecule array |
| Automation | Fully automated | Semi-automated | Manual/Semi-auto |
| FDA-cleared assays | p-tau181, Aβ42/40 | p-tau181, Aβ42/40 | None (research use) |
| Sample types | CSF, Plasma | CSF, Plasma | CSF, Plasma |
| Throughput | 300-600/hr | 60-120/hr | 10-40/hr |
| Menu breadth | 6+ neurodegeneration | 4+ AD specific | 15+ research |
| Cost/test | $$ | $$ | $$$$ |
| Assay | Region | Status | Year |
|---|---|---|---|
| Elecsys p-Tau181 (CSF) | US | FDA 510(k) cleared | 2022 |
| Elecsys Aβ42/40 (CSF) | US | FDA 510(k) cleared | 2022 |
| Elecsys p-Tau181 (CSF) | EU | CE-IVD marked | 2021 |
| Elecsys Aβ42/40 (CSF) | EU | CE-IVD marked | 2021 |
| Elecsys p-Tau217 | EU | CE-IVD marked | 2023 |
| Elecsys p-Tau217 | US | FDA submission | Pending |
Roche continues to expand its neurodegeneration biomarker portfolio:
Roche Diagnostics. Elecsys p-Tau 181 and Aβ42/40 Assays Technical Information. 2024. ↩︎
Thijssen M, et al. Diagnostic performance of plasma p-tau181, p-tau217 and Aβ42/40 with Roche Elecsys. Nat Med. 2024. ↩︎
Teunissen CE, et al. Blood-based biomarkers for Alzheimer's disease. J Neurol Sci. 2023. ↩︎
FDA. 510(k) Summary: Roche Elecsys p-Tau 181. 2022. ↩︎
Schoonenboom S, et al. Performance of Elecsys p-tau181 and Aβ42/40 for AD diagnosis. Alzheimers Dement. 2022. ↩︎
Palmqvist S, et al. Discriminatory accuracy of plasma p-tau217 vs p-tau181. JAMA Neurol. 2023. ↩︎
Janelidze S, et al. Head-to-head comparison of 8 plasma amyloid-beta and p-tau assays. JAMA Neurol. 2021. ↩︎
FDA. 510(k) Summary: Roche Elecsys Aβ42/40. 2022. ↩︎
Khalil M, et al. Neurofilament light chain in CSF and blood. Clin Neuro. 2022. ↩︎
Jack CR Jr, et al. NIA-AA Research Framework: AT(N) classification. Alzheimers Dement. 2018. ↩︎
Boxer AL, et al. Tau biomarkers in 4R tauopathies. Neurology. 2023. ↩︎